



## ORIGINAL ARTICLE

# Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial

Guy G Brusselle,<sup>1</sup> Christine VanderStichele,<sup>1</sup> Paul Jordens,<sup>2</sup> René Deman,<sup>3</sup> Hans Slabbynck,<sup>4</sup> Veerle Ringoet,<sup>5</sup> Geert Verleden,<sup>6</sup> Ingel K Demedts,<sup>7</sup> Katia Verhamme,<sup>8</sup> Anja Delporte,<sup>1</sup> Bénédicte Demeyere,<sup>1</sup> Geert Claeys,<sup>9</sup> Jerina Boelens,<sup>9</sup> Elizaveta Padalko,<sup>9</sup> Johny Verschakelen,<sup>10</sup> Georges Van Maele,<sup>11</sup> Ellen Deschepper,<sup>11</sup> Guy F P Joos<sup>1</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2012-202698>).

For numbered affiliations see end of article.

## Correspondence to

Dr Guy G Brusselle,  
Department of Respiratory  
Medicine, Ghent University  
Hospital, De Pintelaan 185,  
Ghent B-9000, Belgium;  
[guy.brusselle@ugent.be](mailto:guy.brusselle@ugent.be)

Received 7 September 2012  
Revised 13 November 2012  
Accepted 26 November 2012  
Published Online First  
3 January 2013



► <http://dx.doi.org/10.1136/thoraxjnl-2012-203055>  
► <http://dx.doi.org/10.1136/thoraxjnl-2013-203256>

**To cite:** Brusselle GG, VanderStichele C, Jordens P, et al. *Thorax* 2013;**68**:322–329.

## ABSTRACT

**Background** Patients with severe asthma are at increased risk of exacerbations and lower respiratory tract infections (LRTI). Severe asthma is heterogeneous, encompassing eosinophilic and non-eosinophilic (mainly neutrophilic) phenotypes. Patients with neutrophilic airway diseases may benefit from macrolides.

**Methods** We performed a randomised double-blind placebo-controlled trial in subjects with exacerbation-prone severe asthma. Subjects received low-dose azithromycin (n=55) or placebo (n=54) as add-on treatment to combination therapy of inhaled corticosteroids and long-acting  $\beta_2$  agonists for 6 months. The primary outcome was the rate of severe exacerbations and LRTI requiring treatment with antibiotics during the 26-week treatment phase. Secondary efficacy outcomes included lung function and scores on the Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ).

**Results** The rate of primary endpoints (PEPs) during 6 months was not significantly different between the two treatment groups: 0.75 PEPs (95% CI 0.55 to 1.01) per subject in the azithromycin group versus 0.81 PEPs (95% CI 0.61 to 1.09) in the placebo group (p=0.682). In a predefined subgroup analysis according to the inflammatory phenotype, azithromycin was associated with a significantly lower PEP rate than placebo in subjects with non-eosinophilic severe asthma (blood eosinophilia  $\leq 200/\mu\text{l}$ ): 0.44 PEPs (95% CI 0.25 to 0.78) versus 1.03 PEPs (95% CI 0.72 to 1.48) (p=0.013). Azithromycin significantly improved the AQLQ score but there were no significant between-group differences in the ACQ score or lung function. Azithromycin was well tolerated, but was associated with increased oropharyngeal carriage of macrolide-resistant streptococci.

**Conclusions** Azithromycin did not reduce the rate of severe exacerbations and LRTI in patients with severe asthma. However, the significant reduction in the PEP rate in azithromycin-treated patients with non-eosinophilic severe asthma warrants further study.

**ClinicalTrials.gov number** NCT00760838.

## INTRODUCTION

Severe asthma is associated with substantial morbidity, disability and healthcare costs.<sup>1–2</sup> In comparison

## Key messages

### What is the key question?

► Does maintenance treatment with low-dose azithromycin decrease the rate of exacerbations in adult patients with severe asthma and frequent exacerbations?

### What is the bottom line?

► Azithromycin is a new option for prevention of exacerbations in patients with non-eosinophilic severe asthma.

### Why read on?

► Severe asthma is a heterogeneous disease requiring different add-on treatments according to the underlying asthma phenotype (eosinophilic vs non-eosinophilic (eg, neutrophilic) airway inflammation).

with patients with mild-to-moderate asthma, adult patients with severe asthma have a higher need for medications, have more persistent symptoms and impaired lung function. Importantly, subjects with severe asthma have a greater frequency and severity of exacerbations of asthma, which puts them at risk of emergency department visits and hospitalisations.<sup>3</sup> Moreover, severe asthma has been shown to be a risk factor for lower respiratory tract infections (LRTI), including pneumonia.<sup>4</sup>

Asthma is characterised by clinical and biological heterogeneity.<sup>1–4</sup> Besides the well-known allergic eosinophilic asthma phenotype, half of patients with mild-to-moderate asthma have persistently non-eosinophilic disease.<sup>5</sup> Interestingly, peripheral blood eosinophil counts correlate well with sputum eosinophilia, and a threshold of 220 eosinophils/ $\mu\text{l}$  blood was the best biomarker of sputum eosinophilia.<sup>5</sup> Several phenotypes of severe asthma have been discerned by the Severe Asthma Research Program, demonstrating substantial differences in eosinophil and neutrophil counts in sputum.<sup>4</sup> The non-eosinophilic asthma phenotype responds poorly to currently available anti-inflammatory

therapy.<sup>5–6</sup> Subjects with severe asthma are older with longer disease duration, have less atopy by skin tests and frequently need oral corticosteroid courses despite multiple controller medications including high doses of inhaled corticosteroids.<sup>4</sup> Relative corticosteroid insensitivity has indeed been implicated in patients with severe asthma and in smokers with asthma.<sup>7</sup>

Macrolides have immunomodulatory and anti-inflammatory effects in addition to their antibacterial effects.<sup>8</sup> Maintenance treatment with macrolides such as azithromycin has been proved to be effective in chronic neutrophilic airway diseases including cystic fibrosis, bronchiectasis and diffuse panbronchiolitis.<sup>9–12</sup> In an observational study, we have demonstrated the benefits of short-term macrolide treatment in patients with severe asthma.<sup>13</sup> Recently, erythromycin and azithromycin—added to usual therapy—have been shown to prevent exacerbations in patients with chronic obstructive pulmonary disease (COPD), a predominantly neutrophilic airway disease.<sup>14–16</sup>

We conducted a randomised double-blind placebo-controlled trial to test the hypothesis that long-term add-on treatment with azithromycin decreases the frequency of acute exacerbations and LRTI in patients with exacerbation-prone severe asthma. Since severe asthma is a heterogeneous syndrome, we predefined to analyse the efficacy of azithromycin according to the type of underlying inflammation (non-eosinophilic (mainly neutrophilic) or eosinophilic asthma).

## METHODS

### Study patients

Patients were considered eligible if they were 18–75 years of age, had a diagnosis of persistent asthma, a history consistent with Global Initiative for Asthma step 4 or 5 clinical features, received high doses of inhaled corticosteroids ( $\geq 1000$   $\mu\text{g}$  fluticasone or equivalent) plus inhaled long-acting  $\beta_2$  agonists for at least 6 months prior to screening and had had at least two independent severe asthma exacerbations requiring systemic corticosteroids and/or LRTI requiring antibiotics within the previous 12 months. Subjects were never-smokers or ex-smokers with a smoking history of  $\leq 10$  pack-years. Their fractional excretion of exhaled nitric oxide (FeNO) level was below the upper limit of normal. Exclusion criteria are specified in the online supplementary appendix. Patients continued their maintenance treatment with high doses of inhaled corticosteroids and long-acting  $\beta_2$  agonists during the trial.

### Study design and oversight

The AZITHromycin in Severe ASThma (AZISAST) study was a randomised double-blind placebo-controlled parallel-group multicentre study (see online supplementary appendix figure S1). The study protocol was approved by the central ethics committee of Ghent University Hospital, and was reviewed by the local ethics committees at each participating site. All patients provided written informed consent.

### Randomisation and masking

After a 2-week run-in period, patients were randomly assigned in a 1 : 1 ratio to receive add-on treatment with azithromycin or placebo using a central web-based randomisation tool. The hospital pharmacist (Ghent University Hospital) formulated the study drugs: capsules with 250 mg azithromycin (prepared from capsules of Zitromax) or placebo. After randomisation, the patients took one capsule per day for 5 days and then one capsule three times a week. The total treatment period was 26 weeks (until visit 6), with a study drug-free follow-up period of 4 weeks (washout period).

## Assessments

Assessments included asthma and medical history, vital signs, physical examination, electrocardiography, imaging, pulmonary function tests, FeNO measurements, blood testing and questionnaires (including the Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ)). A full description of the assessments is given in the online supplementary appendix.

## Outcomes

The primary efficacy outcome was the rate of primary endpoints (severe asthma exacerbations and/or LRTI requiring antibiotics) during the 26-week treatment phase. Severe asthma exacerbations were defined as deterioration in asthma leading to at least one of the following: (1) hospitalisation; (2) emergency room visit; and/or (3) need for systemic corticosteroids for at least 3 days.<sup>17</sup>

Secondary efficacy outcomes included lung function (forced expiratory volume in 1 s (FEV<sub>1</sub>) pre- and post-bronchodilation), morning and evening peak expiratory flow (PEF), quality of life (AQLQ score) and asthma control (ACQ score). All secondary outcomes were ascertained at visits 2, 3, 4, 5 and 6 (at randomisation and weeks 4, 10, 18 and 26 of the treatment period), except for the questionnaires which were completed by the patient at visits 2, 4 and 6 only. Safety endpoints encompassed adverse events, serious adverse events and adverse events leading to discontinuation.

## Statistical analysis

The primary outcome analysis was conducted within the intention-to-treat population. Unpaired and paired *t* tests were used to assess between- and within-study group differences in symmetrically distributed continuous baseline characteristics and post-treatment outcome measures, respectively. Exact Wilcoxon rank-sum and signed rank tests were used for skewed distributed variables. Proportions were compared between both treatment groups using Fisher exact tests.


Mean primary endpoint rates and mean exacerbation rates per treatment group were investigated using Poisson or negative binomial regression as appropriate.<sup>18</sup> For the first primary endpoint, log rank tests were performed and Kaplan–Meier curves are shown to present the cumulative survival in the placebo and azithromycin arms.

Receiver operating characteristic curve analysis was performed to assess the predictive power of the covariates. Statistical analyses were performed using IBM SPSS statistics V.19 (SPSS Inc, Chicago, Illinois, USA) and R V.2.14.1 (R Foundation for Statistical Computing, Vienna, Austria).

## RESULTS

### Enrolment and baseline characteristics

The flowchart of the AZISAST study is shown in figure 1. A total of 109 of the 120 subjects screened were randomised and constituted the intention-to-treat population. Fifty-five subjects were randomly assigned to receive azithromycin and 54 subjects to receive placebo. Overall, 97% of treatment visits were completed. Seven subjects who withdrew (two in the azithromycin group and five in the placebo group) completed a mean of four visits. Subjects in the two treatment arms were well matched with respect to baseline characteristics (table 1). All patients received high-dose combination therapy of inhaled corticosteroids and long-acting  $\beta_2$  agonists for at least 6 months



**Figure 1** Numbers of patients who were enrolled, assigned to a study group and completed the study. Subjects were recruited by respiratory physicians at the seven participating clinical centres. Patients who completed the 26-week course of the study drug were asked to return 4 weeks later for a washout visit. ULN, upper limit of normal; ITT, intention-to-treat.

prior to study entry and continued this treatment throughout the entire study.

## Efficacy

### Primary outcome

The median treatment period was 183 days in both the azithromycin group and the placebo group ( $p=0.269$ ). During this period a total of 39 primary endpoints (mean rate 0.72 per 26 weeks) occurred in the azithromycin group and 43 primary endpoints (mean rate 0.81 per 26 weeks) in the placebo group ( $p=0.698$ ). In the azithromycin group, 26 (47%) subjects had at least one primary endpoint compared with 26 (48%) in the placebo group (relative risk 0.98, 95% CI 0.68 to 1.43,  $p=1.000$ ). The cumulative survival times based on the first primary endpoint per patient are shown as Kaplan–Meier survival curves for both treatment arms in figure 2A ( $p=0.801$ ). The number of primary endpoints per patient is shown in figure 2B ( $p=0.698$ ).

Thirty severe exacerbations of asthma occurred in the azithromycin group compared with 27 in the placebo group ( $p=1.000$ ). Twenty patients in the azithromycin group and 29 patients in the placebo group experienced a LRTI requiring antibiotics ( $p=0.826$ ). There were two hospital admissions for exacerbations of asthma in the azithromycin group and two in the placebo group ( $p=1.000$ ).

The estimated primary endpoint rate based on a Poisson regression model without adjustment was 0.71 (95% CI 0.52 to 0.97) in the azithromycin group and 0.80 (95% CI 0.59 to

1.07) in the placebo group (estimated primary endpoint rate ratio for azithromycin vs placebo 0.89, 95% CI 0.58 to 1.37,  $p=0.600$ ). After imputation, the estimated adjusted primary endpoint rate during 6 months was 0.75 (95% CI 0.55 to 1.01) in the azithromycin group and 0.81 (95% CI 0.61 to 1.09) in the placebo group (estimated rate ratio 0.92, 95% CI 0.60 to 1.40,  $p=0.682$ ). A negative binomial regression model did not alter the results.<sup>18</sup> When sensitivity analyses restricting the primary endpoint to severe exacerbations of asthma were performed, the estimated severe exacerbation rate based on a Poisson regression model was 0.55 (95% CI 0.38 to 0.78) in the azithromycin group and 0.52 (95% CI 0.36 to 0.75) in the placebo group (estimated primary endpoint rate ratio for azithromycin vs placebo 1.05, 95% CI 0.63 to 1.76,  $p=0.847$ ).

### Predefined subgroup analyses

Since severe asthma is biologically heterogeneous, we performed a predefined subgroup analysis comparing the efficacy of azithromycin depending on blood eosinophilia at baseline. In subjects with severe asthma and blood eosinophilia  $\leq 200/\mu\text{l}$  (non-eosinophilic severe asthma), azithromycin significantly reduced the rate of primary endpoints and of severe exacerbations compared with placebo (figure 2C). The estimated primary endpoint rate for non-eosinophilic severe asthma was 0.44 (95% CI 0.25 to 0.78) in the azithromycin group and 1.03 (95% CI 0.72 to 1.48) in the placebo group (estimated primary endpoint rate ratio for azithromycin vs placebo 0.43, 95% CI 0.22 to 0.84,  $p=0.013$ ). The estimated severe exacerbation rate

**Table 1** Baseline characteristics of subjects in the intention-to-treat population

Characteristic	Placebo (N=54)	Azithromycin (N=55)	p Value
Sex, n			
Male	16 (30%)	26 (47%)	0.077
Female	38 (70%)	29 (53%)	
Age, years			
Median (range), IQR	53 (20–74), (36–60)	53 (19–76), (46–64)	0.097
Age at onset of symptoms, years			
Median (range), IQR	17 (1–72), (6–38)	20 (0–71), (3–40)	0.828
Asthma duration, years			
Median (range) IQR	23 (1–63), (12.8–41.3)	27 (2–70), (11–45)	0.263
Race, n (%) of subjects			
Caucasian	54 (100%)	55 (100%)	–
Body mass index*			
Mean (SD)	26.4 (5.4)	26.5 (4.9)	0.926
Positive atopic status, n (%) of subjects†	38 (70%)	35 (64%)	0.542
Total IgE (IU/ml)			
Median (range), IQR	87.3 (2–4500), (25.2–702.7)	111.3 (1–5000), (30.4–266.0)	0.685
History of nasal polyps, n (%) of subjects	6 (11%)	11 (20%)	0.291
Hospitalisations due to asthma in previous year, n (%) of subjects	13 (24%)	13 (24%)	1.000
Emergency room visits due to asthma in previous year, n (%) of subjects	8 (15%)	4 (7%)	0.237
Severe asthma exacerbations requiring OCS in previous year, n (%) of subjects	47 (87%)	49 (89%)	0.776
LRTI requiring antibiotics in previous year, n (%) of subjects	44 (82%)	46 (84%)	0.805
Severe asthma exacerbations and/or LRTI requiring antibiotics in previous year			
N (mean)	3.0 (1.28)	3.4 (2.08)	0.536
FEV <sub>1</sub> prebronchodilator (% of predicted)			
Mean (SD)	84.8 (20.7)	80.1 (21.9)	0.287
FEV <sub>1</sub> /FVC ratio prebronchodilator			
Mean (SD)	67.8 (12.1)	66.8 (12.3)	0.556
FEV <sub>1</sub> postbronchodilator (% of predicted)			
Mean (SD)	89.3 (19.2)	83.9 (21.7)	0.184
Improvement in FEV <sub>1</sub> after BD use (%)			
Mean (SD)	6.5 (9.0)	5.5 (7.6)	0.959
FeNO (ppb)‡			
Median (range), IQR	17.5 (6–63), (12–27.5)	18.0 (4–54), (14–29)	0.519
Eosinophil count in blood (×10 <sup>9</sup> /l)			
Median (range), IQR	186 (40–1200), (109–354)	208 (0–1240), (100–370)	0.901
Score on ACQ-7			
Mean (SD)	1.7 (1.0)	1.4 (0.9)	0.400
Score on AQLQ			
Mean (SD)	5.2 (1.1)	5.5 (0.9)	0.287
Daily dose of inhaled corticosteroid§ (µg)			
Median (range)	2000 (1000–4000)	2000 (1000–4000)	0.805
Regular use of oral prednisolone			
N (%) of subjects	3 (6%)	9 (16%)	0.124
Daily maintenance dose (mg)			
Median (range)	10 (2.5–17.5)	10 (2.5–10)	0.359
Use of montelukast (LTRA)			
N (%) of subjects	26 (48%)	29 (53%)	0.703

\*Body mass index is the weight in kilograms divided by the square of the height in metres.

†Atopic status based on skin prick tests; if skin prick test was not interpretable or not available, the atopic status is based on serum RAST for standard aeroallergens (house dust mite, animal dander (cat, dog), pollen (grass, tree) and *Aspergillus fumigatus*).


‡FeNO was measured at a flow rate of 50 ml/s and expressed as parts per billion (ppb).

§The doses of inhaled corticosteroids were converted to the equivalent dose of beclomethasone dipropionate and expressed as beclomethasone dipropionate equivalent.

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FeNO, fraction of exhaled nitric oxide; FEV<sub>1</sub>, forced expiratory volume in 1 s; LRTI, lower respiratory tract infection; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroids.

for non-eosinophilic severe asthma was 0.26 (95% CI 0.12 to 0.54) in the azithromycin group and 0.62 (95% CI 0.39 to 0.99) in the placebo group (estimated severe exacerbation rate ratio for azithromycin vs placebo 0.42, 95% CI 0.17 to 1.00,  $p=0.050$ ). In contrast, the primary endpoint rate for

eosinophilic severe asthma was 0.96 (95% CI 0.66 to 1.41) in the azithromycin group compared with 0.50 (95% CI 0.28 to 0.88) in the placebo group (estimated rate ratio 1.93, 95% CI 0.98 to 3.81,  $p=0.058$ ). In patients with eosinophilic severe asthma, the severe exacerbation rate was higher in the



**Figure 2** Primary endpoints during the course of the study. (A) Proportion of participants free from primary endpoints for 26 weeks according to study group. The intention-to-treat analyses were based on the participants who were randomly assigned to azithromycin (N=55) or placebo (N=54). A primary endpoint was defined as a severe asthma exacerbation requiring treatment with systemic corticosteroids, emergency room visit or hospitalisation<sup>17</sup> and/or an acute lower respiratory tract infection requiring treatment with antibiotics. (B) Distribution of the number of primary endpoints among subjects in each study group during the treatment period of the study. (C) Proportion of subjects with non-eosinophilic severe asthma (defined by a fraction of exhaled nitric oxide lower than the upper limit of normal and a blood eosinophilia  $\leq 200/\mu\text{l}$ ) free from primary endpoints for 26 weeks, according to study group (azithromycin or placebo). In subjects with non-eosinophilic asthma, azithromycin significantly decreased the number of patients with at least one primary endpoint (9 of 27 (33%) azithromycin-treated subjects vs 18 of 29 (62%) placebo-treated subjects; relative risk 0.54, 95% CI 0.29 to 0.98,  $p=0.037$ ).

azithromycin group than in the placebo group: 0.82 (95% CI 0.55 to 1.24) versus 0.38 (95% CI 0.20 to 0.72) estimated rate ratio 2.19, 95% CI 1.01 to 4.73,  $p=0.046$ ). In the Poisson regression model there is a significant interaction between the phenotype of severe asthma and treatment arm ( $p=0.002$ ).

#### Other efficacy outcomes

At 26 weeks there was a significant improvement in the AQLQ score in the azithromycin group (0.32, 95% CI 0.08 to 0.57,  $p=0.011$ ) compared with a non-significant trend in the placebo group (0.20, 95% CI  $-0.01$  to 0.41,  $p=0.057$ ; table 2). There were no significant differences between the groups in the change from baseline in AQLQ score (mean difference 0.12; 95% CI  $-0.20$  to 0.44;  $p=0.467$ ).

At 26 weeks, the mean improvement in the ACQ score was  $-0.24$  (95% CI  $-0.50$  to 0.02,  $p=0.068$ ) in the azithromycin group compared with  $-0.12$  (95% CI  $-0.33$  to 0.08,  $p=0.222$ ) in the placebo group (table 2). There were no significant between-group differences in the change from baseline in the

ACQ score (mean difference  $-0.12$ ; 95% CI  $-0.44$  to 0.21;  $p=0.485$ ). There were no significant between-group differences in the changes in FEV<sub>1</sub> (pre- and post-bronchodilator), morning PEF, evening PEF, use of rescue medication and FeNO (table 2).

#### Safety

No significant differences were observed in the frequency of adverse events, serious adverse events or adverse events leading to discontinuation of the study drug (see online supplementary table S1). Importantly, no subject in the azithromycin group reported hearing loss.

#### Oropharyngeal colonisation and resistance to macrolides

Two clinical centres studied resistance to macrolide antibiotics, obtaining oropharyngeal swabs in 46 participants (23 in each treatment arm) at four visits (see online supplemental figure S1). Eleven subjects (47.8%) in the azithromycin group and nine subjects (39.1%) in the placebo group were colonised with erythromycin-resistant streptococci in the oropharynx at

Table 2 Secondary efficacy outcomes

Outcome	At 10 weeks after randomisation				At 26 weeks after randomisation			
	Placebo (N=45–50)Mean (SD)	Azithromycin (N=50–53)Mean (SD)	DifferenceMean (95% CI)	p Value	Placebo (N=45–50)Mean (SD)	Azithromycin (N=47–53)Mean (SD)	DifferenceMean (95% CI)	p Value
Change in ACQ score, baseline to week 10 or 26	–0.04 (0.76)	–0.05 (0.98)	–0.01 (–0.35 to 0.33)	0.940	–0.12 (0.70)	–0.24 (0.93)	–0.12 (–0.44 to 0.21)	0.485
Change in AQLQ total score, baseline to week 10 or 26	0.15 (0.63)	0.24 (0.84)	0.09 (–0.19 to 0.38)	0.509	0.20 (0.73)	0.32 (0.89)	0.12 (–0.20 to 0.44)	0.467
Absolute change in morning PEF, baseline to week 10 or 26 (l/min)	–1.72 (49.97)	–3.30 (42.10)	–1.58 (–20.08 to 16.92)	0.866	–5.77 (48.20)	–1.81 (45.27)	3.96 (–15.40 to 23.32)	0.686
Absolute change in evening PEF, baseline to week 10 or 26 (l/min)	–7.98 (44.66)	–4.11 (36.10)	3.88 (–12.38 to 20.13)	0.637	–4.65 (78.68)	–0.81 (48.47)	3.84 (–23.10 to 30.78)	0.778
Change in pre-BD FEV <sub>1</sub> , baseline to week 10 or 26 (%)	0.92 (9.88)	0.64 (9.99)	–0.28 (–4.11 to 3.54)	0.884	–0.90 (11.79)	–0.02 (10.06)	0.88 (–3.44 to 5.19)	0.688
Change in post-BD FEV <sub>1</sub> , baseline to week 10 or 26 (%)	1.17 (8.88)	0.91 (7.61)	–0.26 (–3.45 to 2.92)	0.870	–0.66 (8.84)	1.29 (12.50)	1.95 (–2.42 to 6.33)	0.378
Change in use of rescue medication (number of puffs per day)	0.26 (2.19)	0.13 (1.18)	–0.13 (–0.83 to 0.56)	0.706	0.24 (2.11)	0.08 (1.14)	–0.16 (–0.88 to 0.55)	0.655
Change in FeNO (ppb), median (Q1; Q3)	2 (–4.5; 5.0)	0 (–4.5; 7.1)	–2	0.676	2.1 (–4.2; 6.0)	0.5 (–6.7; 6.7)	–1.6	0.666

ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; BD, bronchodilator; FeNO, fraction of exhaled nitric oxide; FEV<sub>1</sub>, forced expiratory volume in 1 s; PEF, peak expiratory flow.

randomisation. At the end of the 26-week treatment period, 87% of the subjects in the azithromycin group and 35% of the subjects in the placebo group were colonised with erythromycin-resistant oropharyngeal streptococci ( $p<0.001$ ). During the treatment period the proportion of streptococci resistant to erythromycin increased from 17.2% to 73.8% in the azithromycin group and from 7.9% to 17.3% in the placebo group ( $p<0.001$ ; see online supplemental figure S3). The percentage of macrolide-resistant streptococci numerically decreased from 73.8% to 45.9% in the azithromycin group during the 4-week washout period ( $p=0.104$ ).

## DISCUSSION

In this randomised double-blind placebo-controlled trial in patients with severe asthma, add-on treatment with low-dose azithromycin for 6 months did not decrease the frequency of the primary endpoint (severe exacerbations of asthma and LRTI requiring antibiotics). However, in a predefined subgroup analysis—namely, in subjects with severe non-eosinophilic asthma (as defined by a FeNO lower than the upper limit of normal and a blood eosinophilia  $\leq 200/\mu\text{l}$  (the median value of blood eosinophilia in our ITT population))—add-on treatment with azithromycin was associated with a significant reduction in primary endpoints and in the rate of severe exacerbations. Azithromycin improved quality of life and was well tolerated.

Several studies have examined whether macrolides are beneficial in adult patients with asthma.<sup>19–23</sup> However, interpretation of the studies is difficult because of the heterogeneous study populations, the small number of patients studied and the short study durations (less than 12 weeks).<sup>8–24</sup> Most studies have been performed in patients with mild-to-moderate asthma.<sup>19–21 23 25</sup> In a proof-of-concept study, Simpson and colleagues demonstrated that clarithromycin—as add-on treatment to inhaled corticosteroids for 8 weeks in patients with severe asthma—significantly reduced airway concentrations of interleukin-8 and neutrophil numbers and improved quality of life, especially in patients with refractory non-eosinophilic asthma.<sup>26</sup> However, the duration of this single-centre study was too short and the number of patients too small to examine the effect of macrolides on exacerbations. Also, in our multicentre study, treatment with azithromycin significantly improved quality of life at 26 weeks compared with baseline. In both studies there were no changes in symptom scores, lung function or FeNO levels with macrolide treatment.<sup>26</sup>

Since severe asthma is a heterogeneous syndrome, we predefined to analyse the efficacy of azithromycin according to the asthma phenotype (non-eosinophilic (mainly neutrophilic) or eosinophilic asthma).<sup>1–2</sup> Add-on treatment with azithromycin significantly decreased the rate of primary endpoints and of severe exacerbations in the subgroup of patients with non-eosinophilic severe asthma. In contrast, in subjects with eosinophilic severe asthma, there was a trend towards an increased rate of primary endpoints in the azithromycin group, in line with case reports describing the induction of Churg–Strauss syndrome in patients with eosinophilic asthma receiving add-on treatment with azithromycin.<sup>27</sup>

The beneficial effects of azithromycin in non-eosinophilic severe asthma might be due to antibiotic properties or anti-inflammatory and immunomodulatory effects. Chronic respiratory infection with atypical bacteria such as *Mycoplasma pneumoniae* or *Chlamydophila pneumoniae* might play a role in the pathogenesis of severe asthma.<sup>28</sup> However, a trial of roxithromycin in subjects with asthma and serological evidence of infection with *C pneumoniae* did not improve asthma control,<sup>20</sup>

which is in line with our observations that positive IgG antibodies to *C pneumoniae* did not predict therapeutic efficacy of azithromycin in severe asthma.

Long-term treatment with azithromycin in our study appeared to be safe, since the frequency and severity of adverse events was not different from placebo. In particular, no subjects in the azithromycin-treated group mentioned hearing loss, which contrasts with the hearing decrements reported by Albert *et al* in patients with chronic obstructive pulmonary disease (COPD).<sup>15</sup> The older age of the subjects with COPD, more frequent comorbidities, the higher dose of azithromycin used and the intensive monitoring by means of audiometry in the COPD study might explain this difference. Recently, a retrospective observational database study has suggested a small increased risk of cardiovascular death among patients with a high baseline risk of cardiovascular disease taking azithromycin during 5 days for acute infections.<sup>29</sup> Since we excluded patients with significant cardiovascular disease, a prolonged corrected QT interval or use of drugs known to cause QT prolongation, there were no serious cardiac adverse drug reactions in our study.

A concern of chronic treatment with azithromycin is the induction of resistance to macrolides. Short-term treatment with macrolides induced a significant increase in macrolide-resistant pharyngeal streptococci in healthy volunteers.<sup>30</sup> In our study, long-term treatment with azithromycin was associated with an increased proportion of macrolide-resistant oropharyngeal streptococci, confirming the increased incidence of macrolide resistance in the nasopharyngeal flora in the COPD Clinical Research Network study.<sup>15</sup> However, in both studies, there is no evidence suggesting that colonisation with macrolide-resistant organisms increased the risk of LRTI or pneumonia.

Our study has several strengths, including the double-blind design, web-based randomisation and the concealment of allocation. The AZISAST study also has limitations, including the absence of induced sputum or bronchoscopy to delineate the underlying airway inflammation. However, to maximise the external validity of our study, we did not perform induced sputum examinations since this labour-intensive procedure is mainly performed in specialised tertiary referral centres. Moreover, peripheral blood eosinophilia is a sensitive and specific biomarker for airway eosinophilia, both after allergen challenge and in chronic asthma.<sup>5</sup> Whereas phase II trials of targeted add-on therapies with the anti-interleukin 5 monoclonal antibody mepolizumab in refractory eosinophilic asthma initially requested increased eosinophil counts in sputum,<sup>31</sup> an increased blood eosinophil count has been used as a qualifying inclusion criterion in the phase III trial of mepolizumab (DREAM study).<sup>32</sup> Importantly, a FeNO level below the upper limit of normal was an inclusion criterion in our study to avoid enrolment of patients with exacerbation-prone severe asthma due to non-adherence to inhaled corticosteroids. A high FeNO level (>50 ppb) in a symptomatic patient with an established diagnosis of asthma indeed implies deteriorating eosinophilic airway inflammation, most frequently due to poor adherence to inhaled corticosteroids.<sup>33</sup>

In summary, this is the first randomised controlled trial examining the efficacy and safety of add-on treatment with low-dose azithromycin in adults with exacerbation-prone severe asthma. Although azithromycin was not superior to placebo in the total population, we demonstrated a significant reduction in primary endpoints in non-eosinophilic severe asthma. This observation is biologically plausible, since macrolides have been shown to be effective in neutrophilic chronic airway diseases such as cystic fibrosis (CF), non-CF bronchiectasis, diffuse panbronchiolitis and COPD. The induction of macrolide resistance in the

nasopharyngeal and oropharyngeal flora in azithromycin-treated subjects is of concern. In addition, the long-term effects of macrolide treatment on microbial resistance in the community are not known.

#### Author affiliations

- <sup>1</sup>Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
- <sup>2</sup>Department of Respiratory Medicine, OLV Ziekenhuis, Aalst, Belgium
- <sup>3</sup>Department of Respiratory Medicine, AZ Groeninge, Kortrijk, Belgium
- <sup>4</sup>Department of Respiratory Medicine, ZNA Middelheim, Antwerpen, Belgium
- <sup>5</sup>Department of Respiratory Medicine, AZ Sint-Jan, Brugge, Belgium
- <sup>6</sup>Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven, Belgium
- <sup>7</sup>Department of Respiratory Medicine, Heilig Hart Ziekenhuis, Roeselare, Belgium
- <sup>8</sup>Department of Epidemiology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
- <sup>9</sup>Department of Microbiology, Clinical Chemistry and Immunology, Ghent University Hospital, Ghent, Belgium
- <sup>10</sup>Department of Radiology, University Hospital Gasthuisberg, Leuven, Belgium
- <sup>11</sup>Biostatistics Unit, Department of Public Health, Ghent University Hospital, Ghent, Belgium

**Acknowledgements** We acknowledge all patients, physicians, clinical trial nurses, data managers and other collaborators who contributed to the AZISAST study.

**Contributors** GGB: study design. GGB, CVS, PJ, RD, HS, VR, GVM, IKD, GFPJ: patient recruitment, enrolment, randomisation and follow-up. AD, BD, JV: collection of the data. GC, JB and EP: bacteriological and serological analyses. GGB, CVS, KV, GVM, ED, GFPJ: analysis and interpretation of the data. GGB, GVM, KV, JB, EP, ED, GFPJ: writing of the report.

**Competing interests** None.

**Patient consent** All patients provided written informed consent, as required by Belgian Law and the Ethical Committees involved.

**Ethics approval** The study protocol was approved by the central ethics committee of Ghent University Hospital, and was reviewed by the local ethics committees at each participating site.

**Funding** The AZITHromycin in Severe ASThma (AZISAST) study was an academic clinical trial, without sponsorship from the pharmaceutical industry. The study was funded by the Agency for Innovation by Science and Technology (IWT 70709), Flanders, Belgium. The study sponsor (IWT) had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

**Provenance and peer review** Not commissioned; internally peer reviewed.

#### REFERENCES

- 1 Wenzel SE. Asthma: defining of the persistent adult phenotypes. *Lancet* 2006;368:804–13.
- 2 The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. *Eur Respir J* 2003;22:470–7.
- 3 Haselkorn T, Fish JE, Zeiger RS, *et al*. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. *J Allergy Clin Immunol* 2009;124:895–902 e1–4.
- 4 Moore WC, Meyers DA, Wenzel SE, *et al*. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. *Am J Respir Crit Care Med* 2010;181:315–23.
- 5 McGrath KW, Icitovic N, Boushey HA, *et al*. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. *Am J Respir Crit Care Med* 2012;185:612–19.
- 6 Green RH, Brightling CE, Woltmann G, *et al*. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. *Thorax* 2002;57:875–9.
- 7 Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. *Eur Respir J* 2004;24:822–33.
- 8 Crosbie PAJ, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. *Eur Respir J* 2009;33:171–81.
- 9 Equi A, Balfour-Lynn IM, Bush A, *et al*. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. *Lancet* 2002;360:978–84.
- 10 Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. *Thorax* 2004;59:540–1.
- 11 Wong C, Jayaram L, Karalus N, *et al*. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. *Lancet* 2012;380:660–7.

- 12 Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. *Thorax* 1997;52:915–18.
- 13 Coeman M, van Durme Y, Bauters F, et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. *Thorax* 2011;5:377–86.
- 14 Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. *Am J Respir Crit Care Med* 2008;178:1139–47.
- 15 Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011;365:689–98.
- 16 Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. *Lancet* 2011;378:1015–26.
- 17 Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/ European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. *Am J Respir Crit Care Med* 2009;180:59–99.
- 18 Keene ON, Calverley PM, Jones PW, et al. Statistical analysis of COPD exacerbations. *Eur Respir J* 2008;32:1421–2.
- 19 Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. *Chest* 2002;121:1782–8.
- 20 Black PN, Blasi F, Jenkins CR, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. *Am J Respir Crit Care Med* 2001;164:536–41.
- 21 Shoji T, Yoshida S, Sakamoto H, et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. *Clin Exp Allergy* 1999;29:950–6.
- 22 Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2008;177:148–55.
- 23 Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. *J Allergy Clin Immunol* 2010;126:747–53.
- 24 Richeldi L, Ferrara G, Fabbri LM, et al. Macrolides for chronic asthma. *Cochrane Database Syst Rev* 2005;(4):CD002997.
- 25 Amayasu H, Yoshida S, Ebana S, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. *Ann Allergy Asthma Immunol* 2000;84:594–8.
- 26 Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. *Am J Respir Crit Care Med* 2008;177:148–55.
- 27 Hübner C, Dietz A, Stremmel W, et al. Macrolide-induced Churg-Strauss syndrome in a patient with atopy. *Lancet* 1997;350:563.
- 28 Martin RJ, Kraft M, Chu HW, et al. A link between chronic asthma and chronic infection. *J Allergy Clin Immunol* 2001;107:595–601.
- 29 Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. *N Engl J Med* 2012;366:1881–90.
- 30 Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *Lancet* 2007;369:482–90.
- 31 Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. *N Engl J Med* 2009;360:973–84.
- 32 Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. *Lancet* 2012;380:651–9.
- 33 Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med* 2011;184:602–15.

**Supplemental Appendix:**

**Azithromycin for Prevention of Exacerbations in Severe Asthma:  
the AZISAST study**

G. Brusselle<sup>1</sup>, C. VanderStichele<sup>1</sup>, P. Jordens<sup>2</sup>, R. Deman<sup>3</sup>, H. Slabbynck<sup>4</sup>, V. Ringoet<sup>5</sup>, G. Verleden<sup>6</sup>, I. Demedts<sup>7</sup>, K. Verhamme<sup>8</sup>, A. Delporte<sup>1</sup>, B. Demeyere<sup>1</sup>, G. Claeys<sup>9</sup>, J. Boelens<sup>9</sup>, E. Padalko<sup>9</sup>, J. Verschakelen<sup>10</sup>, G. Van Maele<sup>11</sup>, E. Deschepper<sup>11</sup>, and G. Joos<sup>1</sup>.

<sup>1</sup> Department of Respiratory Medicine, Ghent University Hospital, Ghent;

<sup>2</sup> Department of Respiratory Medicine, OLV Ziekenhuis, Aalst;

<sup>3</sup> Department of Respiratory Medicine, AZ Groeninge, Kortrijk;

<sup>4</sup> Department of Respiratory Medicine, ZNA Middelheim, Antwerpen;

<sup>5</sup> Department of Respiratory Medicine, AZ Sint-Jan, Brugge;

<sup>6</sup> Department of Respiratory Medicine, University Hospital Gasthuisberg, Leuven;

<sup>7</sup> Department of Respiratory Medicine, Heilig Hart Ziekenhuis, Roeselare;

<sup>9</sup> Department of Microbiology, Clinical Chemistry and Immunology, Ghent University Hospital, Ghent;

<sup>10</sup> Department of Radiology, University Hospital Gasthuisberg, Leuven;

<sup>11</sup> Biostatistics Unit, Ghent University Hospital, Ghent;

all in Belgium, and

<sup>8</sup> Department of Epidemiology, Erasmus MC Rotterdam, the Netherlands.

Corresponding author:

Guy Brusselle

Department of Respiratory Medicine

Ghent University Hospital

De Pintelaan 185

B-9000 Ghent; Belgium

Tel: (32)(0)93322600

Fax: (32) (0)93322341

[guy.brusselle@ugent.be](mailto:guy.brusselle@ugent.be)

## **Methods**

### **Study patients**

Inclusion criteria encompassed the following criteria: 18-75 years of age; a diagnosis of persistent asthma for at least 1 year duration; a history consistent with Global Initiative for Asthma (GINA) step 4 or 5 clinical features; patients receiving high doses of inhaled corticosteroids ( $\geq 1000$   $\mu\text{g}$  fluticasone or equivalent) plus inhaled long-acting beta2-agonists for at least 6 months prior to screening; patients suffering multiple (at least two) independent, severe asthma exacerbations requiring treatment with systemic corticosteroids and/or LRTI requiring treatment with antibiotics, within the previous 12 months; never-smokers or ex-smokers with a smoking history of  $\leq 10$  pack-years; and a fractional excretion of exhaled nitric oxide (FeNO) level below the upper limit of normal according to gender, atopic status and smoking history.<sup>1</sup> Subjects with FeNO levels above the upper limit of normal were excluded, since high FeNO levels in symptomatic patients with asthma have been associated with eosinophilic airway inflammation due to persistent allergen exposure or poor adherence to inhaled corticosteroids.<sup>2</sup> All subjects were followed by respiratory physicians, checking and optimizing patient's inhalation technique prior to enrollment into the study. All eligible patients had to have a diagnosis of persistent asthma, according to the Global Initiative for Asthma (GINA) guidelines, implicating the presence of variable airflow obstruction as evidenced by (1) spirometry with acute reversibility testing (pre- and post-bronchodilator FEV<sub>1</sub>), (2) bronchial provocation testing (positive histamine or methacholine challenge test) or (3) peak flow variability. The asthma patients had to fulfill at least one of these criteria of variable airflow obstruction in their medical history.

Exclusion criteria were a prolonged corrected QT interval, severe bronchiectasis, significant medical conditions or significant laboratory abnormalities that might interfere with the study conduct or patient's safety, pregnancy or breastfeeding, prohibited concomitant medication including anti-IgE treatment and treatment with macrolide antibiotics within the last three months.

Patients continued maintenance treatment with high doses inhaled corticosteroids ( $\geq 1000$   $\mu\text{g}$  fluticasone or equivalent) and long-acting beta2-agonists during the trial. Salbutamol 100  $\mu\text{g}$  per puff was provided as rescue medication. In patients under chronic maintenance treatment with oral corticosteroids, the dose was kept stable until visit 3 (after 4 weeks of study drug treatment) and could then be tapered to the lowest possible dose, at the discretion of the investigator.

## **Study design and oversight**

The AZithromycin in Severe ASThma (AZISAST) study was a randomized, double-blind, placebo-controlled, parallel-group, multicenter study (see supplementary appendix Figure S1). After a 2 week run-in period, patients were randomly assigned, in a 1:1 ratio, to receive add-on therapy with either azithromycin or placebo using a central web-based randomisation tool, available at a secured study website to the central study staff. Patients who developed a severe asthma exacerbation or lower respiratory tract infection during the run-in period were to be randomized 6 weeks after recovery from the infection or exacerbation.

The hospital pharmacist at the site of the principal investigator formulated the study drugs: capsules with either 250 mg of azithromycin (prepared from capsules of Zitromax®) or placebo, indistinguishable without chemical analysis. After randomisation, the patients took one capsule per day during 5 days and then one capsule three times a week. Total treatment period was 26 weeks (until Visit 6), with a study-drug-free follow-up period of 4 weeks (Visit 7).

The AZISAST study was an academic clinical trial, without sponsorship from the pharmaceutical industry. The study has been funded by the Agency for Innovation by Science and Technology (IWT 70709), Flanders, Belgium. The principal investigator was the main author of the manuscript; all the authors reviewed the drafts and approved the final text for publication. All authors vouch for the accuracy of the reported data and the fidelity to the study protocol.

The study protocol was approved by the central ethics committee at the site of the principal investigator (Ghent University Hospital, Ghent, Belgium), and was reviewed by the local ethics committees at each participating site. All patients provided written informed consent.

## **Assessments**

At screening, demographic information was recorded, as well as medical history, concomitant medication and an extensive asthma history, including information about atopy and comorbidities. An electrocardiography (ECG), a chest X-ray, a high resolution CT-scan of the chest and blood samples were taken to check exclusion criteria before randomisation.

At each visit, vital signs were measured and a physical examination was performed. Lab tests were repeated at visit 3, 4 and 6 (at week 4, 10 and 26 of the treatment period, respectively; Supplemental Figure S1). Adverse events were assessed at each visit.

### **Lung function**

Assessments included pulmonary function tests, encompassing pre- and postbronchodilator spirometry (performed at each visit), and lung volumes and diffusing capacity of the lung (DLCO) (performed at the start and end of the treatment period). Spirometry was performed according to ATS / ERS task force on Standardisation of Lung Function Testing.<sup>3</sup> Before each spirometry, a FeNO measurement was performed with a Niox or Niox Mino analyser according to the ATS/ERS recommendations.<sup>4</sup>

### **Patient Diary**

Patients kept a diary and recorded the following items during the 2 weeks preceding each study visit: Peak Expiratory Flow (PEF) in the morning and evening (highest of 3 values recorded), number of occasions of inhalation of rescue medication, day and night symptoms. Subjects also reported information about medical consumption related to asthma in their diary.

### **Questionnaires**

The Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ) had to be completed by the patient at visit 2, 4 and 6 (at randomisation, at week 10 and 26 of the treatment period; see Supplemental Figure S1). The EuroQol 5D questionnaire (EQ-5D), a standardised instrument as a measure of health outcome, was completed at visit 2 and visit 6.

### **Serology**

Serology for *Chlamydomphila pneumoniae* and *Mycoplasma pneumoniae* were determined at enrollment and at the end of the treatment phase. Separate blood samples taken at screening (visit 1) and at the end of the treatment period (visit 6) were sent to the central laboratory at Ghent University Hospital to determine IgG and IgM antibodies against *Chlamydomphila pneumoniae* and *Mycoplasma pneumoniae* by SeroCP<sup>TM</sup> Recombinant IgG, SeroCP<sup>TM</sup> Recombinant IgM, SeroMP<sup>TM</sup> Recombinant IgG and SeroMP<sup>TM</sup> Recombinant IgM respectively, all from Savyon Diagnostics (St. Ashdod, Israel). All serological tests were

performed according to the manufacturer's instructions on the BEPIII Behring ELISA processor (Siemens, Munich, Germany).

### **Bacteriological substudy**

In two centers (Ghent University Hospital and OLV Hospital Aalst), we performed a bacteriological sub-study to determine macrolide resistance in streptococci with oropharyngeal swabs<sup>5</sup>, taken at four different visits: visit 2, 3, 6 and 7 (before randomisation, after 4 and 26 weeks of study drug treatment and at the final visit, after a washout period of 4 weeks, respectively; see Supplemental Figure S1).

### **Statistical analysis**

#### **Primary efficacy outcome analysis**

Mean primary endpoint rates and mean exacerbation rates per treatment group were investigated using Poisson or negative binomial regression as appropriate.<sup>6</sup> When subjects withdrew from the study, their number of primary endpoints (exacerbations and LRTI requiring treatment with antibiotics) was adjusted as follows: recorded number of observations + (days remaining/total study period in days) x mean primary endpoint frequency in the study group. As a supporting analysis, and to alternatively account for varying lengths of treatment for patients who dropped out from the trial prematurely, primary endpoint rates and exacerbation rates were calculated for each patient separately and compared between treatment groups using the Wilcoxon rank-sum test.

#### **Sample size calculation**

To have a power of 0.80 (the maximum likelihood of making a type II [false-negative] error being  $\beta = 20\%$ ) and to have a level of statistical significance of 0.05 (two-sided testing with  $\alpha = 0.05$ ), and taking into account an estimated standardized effect size of 0.22 on the primary outcome (the rate of primary endpoints), a sample size of 54 evaluable patients per treatment arm was required. For both groups together, 108 evaluable patients were thus required. Estimating the drop out rate at  $\pm 10\%$ , approximately 120 patients with severe asthma needed to be randomized in the AZISAST study.

## Results

### **Predefined subgroup analysis of response to macrolide treatment according to severe asthma phenotype**

Since severe asthma is biologically heterogeneous, and since macrolides have anti-inflammatory effects in noneosinophilic (neutrophilic) chronic airway diseases, we performed a predefined subgroup analysis comparing the efficacy of azithromycin versus placebo depending on the presence or absence of blood eosinophilia at baseline. In subjects with severe asthma and blood eosinophilia  $\leq 200/\mu\text{L}$  (i.e. noneosinophilic severe asthma), azithromycin significantly reduced the rate of primary endpoints compared to placebo (Figure 2C). Based on a Poisson regression model, the estimated primary endpoint rate for non-eosinophilic severe asthma was 0.44 (95% CI 0.25 to 0.78) in the azithromycin group and 1.03 (95% CI 0.72 to 1.48) in the placebo group ( $P=0.013$ ). In contrast, the primary endpoint rate for eosinophilic severe asthma was 0.96 (95% CI 0.66 to 1.41) in the azithromycin group compared to 0.50 (95% CI 0.28 to 0.88) in the placebo group ( $P=0.058$ ). Importantly, in the Poisson regression model, there is a statistically significant interaction between the (non)eosinophilic phenotype of severe asthma and the treatment arm ( $P=0.002$ ).

In subjects with noneosinophilic asthma, azithromycin also significantly decreased the number of patients with at least one primary endpoint (9 out of 27 [33%] of azithromycin-treated subjects, compared with 18 out of 29 [62%] of placebo-treated subjects; relative risk: 0.54, 95% CI, 0.29 to 0.98,  $P=0.037$ ). In contrast, there was a trend towards a higher percentage of subjects experiencing at least one primary endpoint in patients with severe asthma and blood eosinophilia  $> 200/\mu\text{L}$  (relative risk: 1.67, 95% CI, 0.98 to 2.83,  $P=0.058$ ).

### **Predefined subgroup analysis of response to macrolide treatment according to *Chlamydomydia pneumoniae* serology**

Since *Chlamydomydia pneumoniae* has been associated with severe asthma and accelerated progression of disease, and since macrolides have antibiotic effects towards atypical bacteria, we performed a predefined subgroup analysis comparing the efficacy of azithromycin versus placebo depending on the presence or absence of *C. pneumoniae* immunoglobulin G (IgG) in serum at baseline. A positive *C. pneumoniae* serology, demonstrated in 64% of the ITT population, did not affect the therapeutic response to azithromycin or placebo, as compared with subjects with a negative *C. pneumoniae* serology at baseline (see Supplemental Figure S2). During the 26-weeks treatment phase of the study, one acute *C. pneumoniae* infection and two acute *M. pneumoniae* infections were

demonstrated by IgG seroconversion (as recommended by the IDSA/ATS consensus guidelines).<sup>7</sup>

### **Tapering of oral corticosteroids during the 26-week treatment phase**

At randomization, twelve subjects (nine in the azithromycin group and three in the placebo group) were corticoid-dependent, receiving chronic maintenance treatment with oral corticosteroids at a median dose of 10 mg prednisolone per day. In these patients, the dose was kept stable until visit 3 (after 4 weeks of study drug treatment) and could then be tapered to the lowest possible dose, at the discretion of the investigator. At the end of the treatment phase, the median dose of prednisolone had been reduced to 5 mg per day in the azithromycin arm, whereas the median dose remained 10 mg per day in the placebo arm. In two subjects of the azithromycin group, oral corticosteroid treatment could be stopped.

## Safety

**Supplemental Appendix Table S1: Adverse events**

	Placebo (n=54)	Azithromycin (n=55)	
<b>Adverse events *</b>			
- Subjects (%)	39 (72%)	37 (67%)	0.678
- asthma exacerbation	41	40	
- LRT infection	34	24	
- diarrhoea	8	3	
- nausea	2	1	
- abdominal pain	8	2	
- vertigo	1	2	
- headache	3	4	
- allergic reactions	1	2	
- elevated liver function tests	0	2	
- thrombocytopenia	0	1	
- leucopenia	0	1	
- other	7	6	
- Total adverse events	105	88	
<b>Serious adverse events</b>			
- Subjects (%)	6(11%)	6 (11%)	1.000
- # SAE :			
0	48 (89%)	49 (89%)	
1	6 (11%)	5 (9%)	
2	0 (0%)	1 (2%)	
<b>Drug related adverse events</b>			
- Subjects (%)	3 (6%)	4 (7%)	1.000
- # Drug related adverse event :			
0	51 (94%)	51 (93%)	
1	2 (4%)	2 (4%)	
2	1 (2%)	2 (4%)	
<b>Discontinuation</b>	5 (9%)	2 (4%)	0.271
<b>Discontinuation due to adverse event</b>	2 (4%)	1 (2%)	0.618

Abbreviations: LRT: lower respiratory tract; SAE: serious adverse event.

\* all adverse events till end of study.

## Discussion

### **Similarities between severe asthma and bronchiolitis obliterans syndrome concerning response to treatment with macrolides (azithromycin)**

The differential effect of azithromycin in severe asthma according to the asthma phenotype (noneosinophilic versus eosinophilic asthma) is reminiscent of the effect of azithromycin in chronic rejection or bronchiolitis obliterans syndrome (BOS) after lung transplantation.<sup>8</sup> In observational studies, we have revealed a dichotomy in the pathogenesis and clinical phenotype of BOS, encompassing a neutrophilic reversible allograft dysfunction, responding to azithromycin, and a fibroproliferative BOS, not responding to azithromycin.<sup>8</sup> Azithromycin significantly reduced airway interleukin-8 and neutrophilia in patients with BOS.<sup>9</sup> Importantly, in a double-blind randomized placebo-controlled trial, we have shown that chronic treatment with low-dose azithromycin reduced the prevalence of BOS after lung transplantation.<sup>10</sup>

### **Mechanisms of action of macrolides in non-eosinophilic severe asthma**

The beneficial effects of azithromycin in noneosinophilic severe asthma might be due to antibiotic properties or anti-inflammatory and immunomodulatory effects. Several observations favour the antimicrobial activities of macrolides as mechanism of action: recurrent respiratory infections are associated with frequent exacerbations in adults with difficult-to-treat asthma<sup>11</sup>; severe asthma has been shown to be an independent risk factor for invasive pneumococcal disease<sup>12</sup>; and the microbiome of the lower airways and lungs is altered in patients with asthma compared to healthy controls.<sup>13</sup> Chronic respiratory infection with atypical bacteria such as *Mycoplasma pneumoniae* or *Chlamydia pneumoniae* might play a role in the pathogenesis of severe asthma.<sup>14</sup> A trial of roxithromycin in subjects with asthma and serological evidence of infection with *C. pneumoniae* did not lead to sustained improvements of asthma control<sup>15</sup>, which is in line with our observations that positive IgG antibodies to *C. pneumoniae* did not predict therapeutic efficacy of azithromycin in severe asthma. Although application of polymerase chain reaction (PCR) on bronchoalveolar lavage fluid or endobronchial biopsies is considered the gold standard to differentiate between subjects with true chronic *C. pneumoniae* infection and those previously exposed but not

currently infected<sup>16</sup>, only 12 out of 92 patients in the Asthma Clinical Research Network trial with clarithromycin had PCR evidence of infection.<sup>17</sup>


## References

1. Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, Pritchard A, et al. Reference Ranges for Exhaled Nitric Oxide Derived from a Random Community Survey of Adults. *American Journal of Respiratory and Critical Care Medicine*. 2007 August 1, 2007;176(3):238-42.
2. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications 10.1164/rccm.9120-11ST. *Am J Respir Crit Care Med*. 2011 September 1, 2011;184(5):602-15.
3. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J*. 2005 Aug;26(2):319-38.
4. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. *Am J Respir Crit Care Med*. 2005 April 15, 2005;171(8):912-30.
5. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. *The Lancet*. 2007;369(9560):482-90.
6. Keene ON, Calverley PM, Jones PW, Vestbo J, Anderson JA. Statistical analysis of COPD exacerbations. *Eur Respir J*. 2008 Nov;32(5):1421-2.
7. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007 Mar 1;44 Suppl 2:S27-72.
8. Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De Wever W, Verbeken EK, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. *Eur Resp J*. 2008 October 1, 2008;32(4):832-42.
9. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients with Bronchiolitis Obliterans Syndrome. *American Journal of Respiratory and Critical Care Medicine*. 2006 September 1, 2006;174(5):566-70.
10. Vos R, Vanaudenaerde BM, Verleden SE, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. *Eur Resp J*. 2011 January 1, 2011;37(1):164-72.
11. ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. *Eur Resp J*. 2005 November 1, 2005;26(5):812-8.
12. Talbot TR, Hartert TV, Mitchel E, Halasa NB, Arbogast PG, Poehling KA, et al. Asthma as a Risk Factor for Invasive Pneumococcal Disease. *N Engl J Med*. 2005 May 19, 2005;352(20):2082-90.
13. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, et al. Disordered microbial communities in asthmatic airways. *PLoS One*. 2010;5(1):e8578.
14. Martin RJ, Kraft M, Chu HW, Berns EA, Cassell GH. A link between chronic asthma and chronic infection. *Journal of Allergy and Clinical Immunology*. 2001;107(4):595-601.
15. BLACK PN, BLASI F, JENKINS CR, SCICCHITANO R, MILLS GD, RUBINFELD AR, et al. Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of

Infection with *Chlamydia pneumoniae*. American Journal of Respiratory and Critical Care Medicine. 2001 August 15, 2001;164(4):536-41.


16. Kraft M, Cassell GH, Pak J, Martin RJ. *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in asthma: effect of clarithromycin. Chest. 2002 Jun;121(6):1782-8.

17. Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. Journal of Allergy and Clinical Immunology. 2010;126(4):747-53.




**Supplemental Figure S2. Primary Endpoints According to Serology for *Chlamydomophila pneumoniae*.**

Panel A shows the proportion of participants free from primary endpoints for 26 weeks, according to study group, in subjects with negative immunoglobulin G (IgG) to *C. pneumoniae* at baseline. Panel B shows the proportion of participants free from primary endpoints for 26 weeks, according to study group, in subjects with positive IgG to *C. pneumoniae* at baseline. A primary endpoint was defined as a severe asthma exacerbation requiring treatment with systemic corticosteroids, emergency room visit or hospitalisation<sup>17</sup>, and/or an acute lower respiratory tract infection requiring treatment with antibiotics.



Proportion of patients free from primary endpoints  
for 26 weeks

Positive Chlamydophila IgG serology at baseline



### Supplemental Figure S3. Resistance to macrolides.

Temporal changes in the proportion of macrolide resistant oropharyngeal streptococci in the azithromycin and placebo group. Data of 23 patients in each arm. Error bars indicate standard error of the mean (SEM).

In the azithromycin group, there is a significant increase in the proportion of macrolide resistant streptococci at day 30 and day 180 compared to baseline ( $P=0.01$  and  $P=0.0004$ , respectively), and compared to the placebo group ( $P=0.002$  at Day 180).

